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Abstract
Background: Granulosa cell tumors (GCTs) are derived from proliferating granulosa cells of the ovarian follicle. They
are known for their late recurrence and most patients with an aggressive form die from their disease. There are
no treatment options for this slowly proliferating tumor besides surgery and chemotherapy. In a number of tumors,
analogs of the second mitochondria-derived activator of caspases (SMAC), alone or in combination with other molecules,
such as TNFα, are evolving as new treatment options. SMAC mimetics block inhibitor of apoptosis proteins (IAPs), which
bind caspases (e.g. XIAP), or activate the pro-survival NF-κB pathway (e.g. cIAP1/2). Expression of IAPs by GCTs is yet not
fully elucidated but recently XIAP and its inhibition by SMAC mimetics in a combination therapy was described to induce
apoptosis in a GCT cell line, KGN. We evaluated the expression of cIAP1 in GCTs and elucidated the effects of the SMAC
mimetic BV-6 using KGN as a model.
Results: Employing immunohistochemistry, we observed cIAP1 expression in a tissue microarray (TMA) of 42 GCT samples.
RT-PCR confirmed expression of cIAP1/2, as well as XIAP, in primary, patient-derived GCTs and in KGN. We therefore tested
the ability of the bivalent SMAC mimetic BV-6, which is known to inhibit cIAP1/2 and XIAP, to induce cell death in KGN. A
dose response study indicated an EC50≈ 8 μM for both, early (< 8) and advanced (> 80) passages, which differ in growth rate
and presumably aggressiveness. Quantitative RT-PCR showed upregulation of NF-κB regulated genes in BV-6 stimulated cells.
Blocking experiments with the pan-caspase inhibitor Z-VAD-FMK indicated caspase-dependence. A concentration of 20 μM
Z-VAD-FMK was sufficient to significantly reduce apoptosis. This cell death was further substantiated by results of Western
Blot studies. Cleaved caspase 3 and cleaved PARP became evident in the BV-6 treated group.
Conclusions: Taken together, the results show that BV-6 is able to induce apoptosis in KGN cells. This approach may
therefore offer a promising therapeutic avenue to treat GCTs.
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Background
Apoptosis can be activated via two different pathways, the
extrinsic death receptor pathway and the intrinsic mito-
chondria associated pathway [1, 2]. Both will execute apop-
tosis by cleaving and therefore activating caspases, which in
turn degrade other proteins, based on their peptidase activ-
ity [3]. The intrinsic pathway is induced by the release of
pro-apoptotic molecules from mitochondria, for ex-
ample cytochrome c, endonuclease G, apoptosis inducing
factor (AIF), high temperature requirement protein A2
(HtrA2 also known as OMI) or the second mitochondria-
derived activator of caspases (SMAC; or its murine homo-
log, known as direct inhibitor of apoptosis protein binding
protein with low PI (DIABLO)) [2, 4].
SMAC blocks inhibitor of apoptosis proteins (IAPs, e.g.
baculoviral IAP repeat containing protein 1–8, BIRC1–8),
which are highly expressed in various tumors [5]. There-
fore, IAPs are potential targets in oncology. Different
SMAC mimetics have been developed to target IAPs [6–8].
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Some of these compounds are monovalent and others are
bivalent. The latter target two BIR domains simultaneously
and have been shown to be more potent [6, 9].
BIRC2 (cIAP1), BIRC3 (cIAP2), and BIRC4 (XIAP) are
expressed in granulosa cells of ovarian follicles [10]. Tumors,
which arise from these cells (granulosa cell tumors (GCTs)),
are often steroidogenic and produce estrogen in prepubertal
(juvenile GCTs) and postmenopausal woman (adult GCTs)
[11]. Adult GCTs usually bear the FOXL2(C134W) muta-
tion. Although these tumors are steroidogenic, it remains
unknown whether they grow in a gonadotropin-dependent
manner, as shown for other tumors [12, 13].
The majority of patients who suffer from aggressive or
recurrent GCTs, where the aggressiveness and probability
of relapse is not reflected histologically, die from their dis-
ease [11]. Due to the low proliferation speed, chemother-
apy is often ineffective and therefore surgery is the only
promising way to treat GCTs. In other ovarian malignan-
cies, such as epithelial cancers, chemotherapy is more ef-
fective. In these tumors it was shown that reoccurrence
might be due to reduced immune-surveillance or drug-re-
sistant cells [14, 15]. In GCTs this option was never dis-
cussed but might be of interest in the rare case of
effective first line chemotherapy.
To improve the situation for GCT-patients, it is im-
portant to develop alternative methods. A widely used
model to study this type of tumor is the KGN cell line
[16]. These cells are steroidogenic and bear the FOXL2
mutation. It was recently shown that BIRC2 (cIAP1) and
BIRC4 (XIAP) are expressed in GCTs and in KGN [17].
The examined samples were, however, only very weakly
stained for BIRC2 (cIAP1) and reportedly negative for
BIRC3 (cIAP2). Immunostaining results, as those men-
tioned, may depend on fixation, antibody specificity and
antibody concentration. Negative results do not neces-
sarily rule out expression. Furthermore, in granulosa
cells of healthy woman BIRC2, BIRC3 and BIRC4 ex-
pression levels vary during follicular development [18].
Of note, GCTs are thought to stem from proliferating
GCs of unknown follicular stage. In the present study
we therefore examined expression of BIRC2 (cIAP1) in
42 GCTs. We next evaluated the actions of the bivalent
SMAC mimetic BV-6, which targets XIAP and cIAP1/2
simultaneously, in studies employing KGN.
Results
cIAP1 protein expression in GCTs
We examined cIAP1 expression in 42 ovarian GCTs using a
specific anti-cIAP1 antibody. In general, three distinct stain-
ing patterns were observed: strong, weak and heterogeneous
(Fig. 1a-d). Classification of the tumor-staining by 6 individ-
uals revealed 18.2 +/− 1.6 (43.3%) samples with homoge-
nously strong cIAP1 expression (Fig. 1a,d), whereas weak
expression was observed in only 5.8 +/− 1.3 tumors (13.9%)
(Fig. 1b,d). Heterogeneous staining was found in 18.0 +/−
0.9 samples (42.9%) (Fig. 1c,d). In these samples, some cells
showed strong nuclear cIAP1 staining (indicated by arrows),
some remained unstained, and others showed weak staining
in the cytoplasm. A significant difference (****p < 0.0001)
was found between the number of strongly versus weakly
stained tumors and between the number of heterogeneously
versus weakly stained tumors. Negative controls (non-im-
mune rabbit serum instead of antiserum) showed only mar-
ginal and non-specific staining (Fig. 1a, Inset).
BIRC2, BIRC3 and BIRC4 mRNA is expressed in GCTs and
KGN
To elucidate gene expression of IAPs in primary GCT-
samples, we conducted a RT-PCR analysis using the listed
primers (Table 1). BIRC2, BIRC3, and BIRC4 gene expres-
sion levels were analyzed in three human GCTs, as well as
in KGN. All targets were found in the tested samples (Fig.
1e). The band intensities varied across different tumors,
indicating patient-specific expression levels.
BV-6 induces time-dependent cell death in KGN
IAPs are potential targets for tumor treatment. Therefore,
we tested the ability of BV-6, a bivalent SMAC mimetic, to
induce cell death in KGN [6]. This cell line is known to div-
ide faster in high passages, implicating elevated aggressive-
ness [19]. Therefore, we examined BV-6 actions in KGN
from high (> 80, Fig. 2) and low passages (< 8). (A flowchart
of the experiments can be found in the Additional file 1:
Figure S1a). Using live cell imaging, we tested 4 concentra-
tions of BV-6, ranging from 0.1 to 50 μM (Fig. 2a), in com-
parison to the respective solvent controls (Fig. 2a insets). At
low concentrations of BV-6 (0.1 μM, 1 μM) cells were not
affected within the timeframe of 24 h. At 10 μM, BV-6 in-
duced cell death, as seen by detached and floating cells.
This effect was intensified when 50 μM of BV-6 was used.
The concentration-dependent effects were independent of
the passage number (data not shown).
To determine the half maximal effective concentration
(EC50) after 24 h, KGN (passages > 80) were treated with
increasing concentrations of BV-6 for 24 h and
then counted (Fig. 2b). As expected, at low concentrations
(0.1–5.0 μM) cells remained unaffected. However, concen-
trations above 5 μM reduced cell numbers. Nonlinear re-
gression analysis described a sigmoidal curve and
interpolation revealed an EC50 for BV-6 ranging from
7.4 μM to 8.2 μM (Fig. 2b, left graph). For the low passages,
we found an EC50 ranging between 8.1 and 8.6 μM (Fig.
2c). As the effective concentrations did not substantially
vary between high and low passages, all further experi-
ments were implemented on KGN at high passages (> 80).
To further test the defined EC50, cell viability was ana-
lyzed using an ATP assay (Fig. 2b, right graph). For this
purpose, cells were treated with different concentrations
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Fig. 1 BIRC2 (cIAP1), BIRC3 and BIRC4 expression in GCTs and KGN. Identification of BIRC2, BIRC3 and BIRC4 expression at mRNA level in KGN and
GCTs and evaluation of cIAP1 protein expression in GCTs. (a-d) Expression of cIAP1 in 42 different samples of GCTs were analyzed by immunohistochemistry.
(a,d) Results of the evaluation, performed by 6 researchers, indicated strong and homogenous cIAP1 staining in 18.2 tumors (mean). (b,d) 5.8 tumors (mean)
showed weak cIAP1 staining. (c,d) Heterogeneous cIAP1 staining was visible in 18.0 tumors (mean). Arrows indicate strongly stained nuclei. (a-c) Negative
control (rabbit serum) showed no staining (a, inset). Scale bars correspond to 50 μM. (d) Shown are the mean values and SEM. (e) RT-PCR of three
independent GCTs and KGN (primers are described in Table 1). Controls consisted of a no reverse transcription (−RT) sample and a no template
(H2O) sample
Table 1 List of oligonucleotide primers used for RT-PCR studies
Target Sequence (5′ – 3′) Reference Product size (bp)
BIRC2 Forward GAC ATC ATC ATT GCG ACC CAC NM_001166.4 192
Reverse TGG TTT CCA AGG TGT GAG TAC T
BIRC3 Forward AGA ACA CCT GAG ACA TTT TCC CA NM_001165.4 202
Reverse GAC ATC ATC ATC GTT ACC CAC A
BIRC4 Forward TGT GGA GGA GGG CTA ACT GA NM_001167.3 83
Reverse AGA TAT TTG CAC CCT GGA TAC CA
TNFα Forward ATG AGC ACT GAA AGC ATG ATC C NM_000594.4 217
Reverse GAG GGC TGA TTA GAG AGA GGT C
MCP-1 Forward AGG TGA CTG GGG CAT TGA T NM_002982.3 109
Reverse GCC TCC AGC ATG AAA GTC TC
IL8 Forward TCT TGG CAG CCT TCC TGA NM_000584.4 271
Reverse GAA TTC TCA GCC CTC TTC
L19 Forward AGG CAC ATG GGC ATA GGT AA NM_000981.3 199
Reverse CCA TGA GAA TCC GCT TGT TT
HPRT Forward CCT GGC GTC GTG ATT AGT GA NM_000194.2 163
Reverse GGC CTC CCA TCT CCT TCA TC
PPIA Forward AGA CAA GGT CCC AAA GAC NM_021130.5 118
Reverse ACC ACC CTG ACA CAT AAA
TBP Forward TGC ACA GGA GCC AAG AGT GAA NM_003194.5 132
Reverse CAC ATC ACA GCT CCC CAC CA
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of BV-6 (0.1 to 50 μM) and evaluated after 24 h. In ac-
cordance with the results in Fig. 2b, nonlinear regression
analysis revealed a half-maximal reduction of viability by
7.2 to 9.7 μM BV-6. Live cell imaging and subsequent
measurement of confluency were assessed in BV-6
(EC50, 8 μM) treated KGN. The space occupied by cells
(confluency) relative to the maximally available space,
was measured in 20min intervals. Confluency began to
decline after 12 h and reached 0.58 after 24 h, as com-
pared to the control (1.0). This result is in line with the
other experiments. Taken together, we found an EC50
(24 h) of approximately 8 μM for BV-6 in KGN, which is
passage-independent but time-dependent.
BV-6 leads to NF-κB activation and apoptosis in KGN
BV-6 is known to block XIAP, cIAP1 and cIAP2 and
therefore is able to activate apoptosis through different
pathways, including NF-κB activation and direct caspase
activation [6]. To examine these possibilities in KGN, we
exposed KGN to BV-6 (EC50) for 24 h and examined in-
volvement of NF-κB pathway and caspase activation.
IL8, MCP-1, TNFα, BIRC2, BIRC3 and BIRC4 are known
NF-κB target genes [20–23]. Therefore, upregulation points
to pathway activation. Indeed, all of the tested genes were
expressed in BV-6 stimulated KGN (Fig. 3a). BIRC4, BIRC2,
BIRC3 and IL8 were upregulated with a fold-change rate of
1.52 +/− 0.04, 2.4 +/− 0.26, 64.9 +/− 2.57 and 133.5 +/−
14.9, respectively (**p < 0.01 for BIRC2, ***p < 0.001 for
BIRC4 and ****p < 0.0001 for BIRC3 and IL8). TNFα and
MCP-1 were not found in untreated KGN but were present
in BV-6 treated samples, as shown in the representative
agarose gel (Fig. 3a).
To test involvement of caspases, different concentra-
tions of Z-VAD-FMK in combination with BV-6 (EC50,
Fig. 3b) were added to KGN cultures. Z-VAD-FMK is a
pan-caspase inhibitor and therefore functions as a
blocker of apoptosis [24]. Cell viability was assessed
using ATP assays. At low concentrations (1 μM and
5 μM) Z-VAD-FMK had no effect on BV-6 induced cell
death. Interestingly, viability was significantly improved
at higher doses (20 μM ***p < 0.001, 50 μM ****p <
0.0001 and 200 μM ***p < 0.001).
Fig. 2 Effects of BV-6 treatment on KGN. The SMAC mimetic BV-6 was used in different cell viability assays to explore the effects on KGN.
Different BV-6 concentrations (0.05–100 μM) were tested. (a) Live cell images of KGN (passages > 80) treated with BV-6 (0.1, 1, 10 and 50 μM) for
24 h. Corresponding solvent controls are shown in insets. At 0.1 and 1 μM no indications for cell death were evident. At 10 μM detached cells
were visible. At 50 μM all cells detached. Scale bar indicates 50 μm. (b, left graph) Subsequent cell counting analysis of KGN (passages > 80)
treated with BV-6 (0.05–100 μM) revealed an EC50 of 7.4–8.2 μM after nonlinear regression analysis. (n = 3, bars indicate SEM). (b, right graph) ATP
assay with BV-6 (0.1–100 μM) confirmed the cell counting experiment. Nonlinear regression analysis revealed an EC50 ranging from 7.2 to 9.7 μM.
(n = 4, error bars indicate SEM). (c) To examine a possible involvement of the passage number, KGN from early passages (< 8) were stimulated
with BV-6 (0.05–100 μM) for 24 h and then counted. Nonlinear regression analysis revealed an EC50 of 8.1 - 8.6 μM. (d) time dependence was
evaluated by confluency measurement (20 min intervals) of BV-6 (EC50, 8 μM) treated KGN. Data were normalized to the solvent control. Decline
in confluency started after 12 h and reached 0.58 (control =1.0) after 24 h. (n = 3, error bars indicate SEM, rel. = relative)
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Next we screened BV-6-treated KGN for apoptotic
markers by Western Blot. We used a specific anti-cleaved
caspase 3 (α-clCASP3) antibody to detect the intermediate
step of apoptosis and anti-cleaved poly (ADP-ribose)-poly-
merase (α-clPARP) antibody to detect the terminal step of
apoptosis [1, 25]. Both, clCASP3 (Fig. 3c) and clPARP
(Fig. 3d) were present in three independent samples of
BV-6 (8 μM)-treated KGN but completely absent from the
corresponding controls. Using an anti-βActin antibody,
equal loading was confirmed.
Discussion
A hallmark of cancer is resistance to cell death [26],
which may be related to altered IAP expression profiles.
cIAP1 and cIAP2, for example, have been shown to be
overexpressed in various tumors, including cervical can-
cer, esophageal squamous cell carcinoma, hepatocarci-
noma, medulloblastoma, several forms of lung cancer,
pancreatic cancer and many more, as summarized by
Dubrez et al. [27]. SMAC mimetics, which target intracel-
lular IAPs, are for this reason a hot topic in cancer biol-
ogy. Some of these compounds are currently being tested
in phase I and phase II clinical trials and show promising
results [28]. To our knowledge (https://www.clinicaltrials.
gov), there are several ongoing clinical studies with SMAC
mimetics in different solid tumors and lymphomas, how-
ever not in GCTs.
Which IAPs are expressed by GCTs is not fully known.
Yet a recent work described strong and homogenous ex-
pression of XIAP but a weak cIAP1 expression in GCTs
Fig. 3 Classification of cell death induced by BV-6 in KGN. Results of qRT-PCR, ATP-assay and Western Blot experiments performed to classify BV-6
induced cell death. (a) To test NF-κB pathway activation, qRT-PCR experiments of known target genes (BIRC4, BIRC2, BIRC3, IL8, TNFα and MCP-1)
were performed. (a, upper graph) BIRC4, BIRC2, BIRC3 and IL8 levels were significantly increased after BV-6 stimulation (n = 5, geometric mean with
95% confidence interval, **p < 0.01, ***p < 0.001, ****p < 0.0001). (a, lower panels) MCP-1 and TNFα, both were absent in untreated samples but
expressed in BV-6-treated samples (n = 5). Agarose gel shows a representative picture. The controls lacked template (H2O) or reverse transcriptase
(−RT control). (b) ATP-assay was conducted in KGN that were stimulated with a combination of Z-VAD-FMK (1, 5, 20, 50, 200 μM) and BV-6 (EC50,
8 μM) for 24 h. Afterwards luminescence was normalized to cells solely treated with BV-6 (EC50, 8 μM). 1 μM and 5 μM Z-VAD-FMK had no effect
on BV-6 induced cell death. 20 μM, 50 μM and 200 μM Z-VAD-FMK significantly reduced BV-6 induced cell death. (n = 4, mean and SEM, ***p <
0.001, ****p < 0.0001). (c,d) Western Blot analysis using specific α-clCASP3-, α-clPARP- and α-βActin -antibodies. KGN, treated with BV-6 (EC50, 8 μM)
for 24 h were analyzed in comparison to controls. Western Blot revealed cleavage of (c) CASP3 and (d) PARP. The solvent treated controls lacked
any apoptosis relevant signal but the loading control showed equal loading (n = 3, error bars indicate SEM)
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[17]. Immunostaining results may depend on fixation,
antibody specificity, as well as many other factors. There-
fore, we tested a validated and specific anti-cIAP1 anti-
body in 42 tumor samples and employed primary GCT
samples and KGN for RT-PCR studies. While expression
of cIAP1 was strong in most tested GCT samples, the
second largest group showed heterogeneous staining.
Only a small fraction (13.9%) was weakly stained.
Furthermore, we detected BIRC3 (cIAP2) mRNA, which
in the previous study was not described [17], but was
shown to be upregulated in many other tumors [27]. How-
ever, in line with the previous study by Leung et al., BIRC4
(XIAP) was detected. Thus, GCTs are endowed with several
IAPs, which render them targets for SMAC mimetics.
Given that BIRC2, 3 and 4 are present, we hypothesized
that BV-6 may be of special interest [6]. BV-6 targets
cIAP1/2 and XIAP, which block apoptosis by directly inhi-
biting caspases (e.g. XIAP = BIRC4), and by activating the
pro-survival canonical NF-κB pathway (e.g. cIAP1/2 =
BIRC2/3) [6]. We tested BV-6 actions in KGN, a cell line
that is widely used for the study of GCTs [16]. NF-κB was
shown to play a role in BV-6 mediated apoptosis [6]. BV-6
stimulation increased the levels of several target genes of
this pathway, namely IL8, MCP-1, TNFα, BIRC2, BIRC3
and BIRC4 in KGN [20–23]. Interestingly, the increase in
expression of the 3 tested IAPs varied, with BIRC3 (cIAP2)
showing the strongest effect (fold change = 133.5). It may
be possible that upregulation of BIRC2 and BIRC3 are cel-
lular attempts to counter apoptosis [21]. TNFα plays an
important role in BV-6 induced cell death in many tumor
cell lines and is expressed upon BV-6 stimulation in KGN.
Therefore, TNF receptor mediated activation of NF-κB
and apoptosis are likely to be involved in BV-6 actions in
KGN [6]. As we did not elucidate the whole pathway,
e.g. RIP1 ubiquitination and cIAP1/2 degradation, we can
not conclude to the full mode of action of BV-6. However,
it is likely that cIAP1/2, which ubiquitinate RIP1, are de-
graded. In turn this may lead to deubiquitylation of RIP1
and subsequently activation of apoptosis or necroptosis
through a TNFα autocrine loop [6, 29, 30].
Passaging KGN induces a change in proliferation speed,
which might be related to tumor aggressiveness [19]. We
tested low and advanced passages for their sensitivity to
BV-6 but found no substantial differences. BV-6 -induced
cell death in KGN was concentration- (EC50 ≈ 8 μM) and
time-dependent. Low concentrations of BV-6 (e.g. 1 μM)
induced cell death in KGN, but longer incubation times
(72 h) were needed (Additional file 1: Figure S1b).
In a recent study, a SMAC mimetic alone was reported
incapable to induce cell death in KGN [17], but co-applied
with a PPARγ agonist it became effective. The PPARγ
pathway was shown to be relevant in cancer earlier [31, 32].
In the previous study the bivalent SMAC mimetic “com-
pound A”, originally developed by the pioneering group
around Vince [7] was employed. This compound was de-
signed to bind the same IAP domains (BIR2-BIR3) as BV-6,
but is chemically different, which could explain the dispar-
ate potency [6, 7]. Our results obtained with BV-6 are in
line with published work, verifying that some SMAC
mimetics induce cell death as single agents in various
cancers [6, 33–37].
The Western Blot experiments of our study showed
cleaved caspase 3, indicating an intermediate step of apop-
tosis and cleaved PARP, i.e. a terminal step of apoptosis in
BV-6-treated KGN. Furthermore, blocking experiments
with the pan-caspase blocker Z-VAD-FMK improved
KGN viability [24]. Hence, we conclude that BV-6-induced
cell death is mainly apoptosis. Necroptosis (regulated ne-
crosis) has also been described in literature to occur upon
SMAC mimetic stimulation in some settings [38]. It is pos-
tulated that different cell death pathways are interlinked
and might be triggered simultaneously [39]. We attempted
to determine a possible involvement of necroptosis and
examined phosphorylated MLKL (T357/S358) in BV-6-
treated samples by Western Blot, using a validated phos-
phospecific antibody [40]. Using this marker, we were not
able to find signs for necroptotic cell death in KGN. MLKL
was evident in every sample but phosphorylation and sub-
sequently oligomerization were not observed (Additional
file 1: Figure S1c).
The results obtained in cellular studies are in line with
reports showing that apoptosis is induced by BV-6 in
many cell types [6], but the effects of different SMAC
mimetics in distinct experiment settings and cells may
vary. For example, it was found that a SMAC mimetic
monotherapy is effective only in a small number of tumor
cell lines (< 15%), whereas in combination with exogen-
ously added TNFα or TRAIL, around 50% of the tumor
cell lines died [41]. Further, the dependence on cytokines
was proposed. In mouse models, for example, it was
shown that next to the innate immune system the adap-
tive immune system plays an important role in SMAC mi-
metic-mediated cell death [42]. The fact that these
compounds not only affect the tumor cell itself but also
trigger effector cells like natural killer cells, was shown
recently [43]. Lecis and group further supported this hy-
pothesis, as SMAC mimetics affected the tumor niche by
exerting immunomodulatory effects on macrophages [44].
Thus, next to their effect on tumor cells, SMAC mimetics
have a broad impact on the tumor microenvironment and
the immune system. These points can however not be ex-
amined in cellular experiments with KGN cells.
In the present work we focused on the SMAC mimetic
BV-6 as a potential inducer of apoptosis in KGN. As
described, apoptosis is either induced extrinsically (death
receptor pathway) or intrinsically (mitochondrial path-
way). The extrinsic pathway is executed upon binding of
a death ligand (e.g. TNFα) to the corresponding receptor
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(e.g. TNFR1). Then initiator caspase (caspase 8) is
activated, which leads to further cascaded reactions
including caspase 3 activation and cleavage of crucial
proteins, including PARP [25, 45]. These steps were
readily observed in BV-6-treated KGN and indicate that
BV-6 does induce apoptosis.
Taken together, our results may imply that GCTs,
which as we found are often positive for cIAP1, albeit in
a patient-depended manner, can possibly be treated by
BV-6. The results further suggest that prior to treat-
ment, testing for expression of IAPs may be useful and
should be performed.
Conclusions
The SMAC mimetic BV-6 is able to induce apoptosis in
KGN, which express XIAP and cIAP1/2. The results
imply that these IAPs, if present in primary tumors, may
serve as targets for therapeutic approaches.
Methods
Human GCT samples
The ethical committee of the LMU has approved the study
(project 390–15) and patients had agreed to the use of the
tissue. Samples (approximately 0.5 cm3) from three patients
(age 41, 53 and 66 years) undergoing surgery were ob-
tained. Tumor cells were enriched by collagenase digestion
in the presence of antibiotics (1% penicillin/streptomycin
(Biochrom GmbH, Berlin, Germany)) and subsequent plat-
ing on culture wells (HAM’s-F12 supplemented with 10%
fetal calf serum (FCS)), as described for primary human
granulosa cell cultures [26]. RNA was extracted and sub-
jected to RT-PCR.
All patients were diagnosed at the Institute for Path-
ology (LMU, Munich). The diagnoses were confirmed by
an experienced gynecologic pathologist (D.M.).
In addition, two tissue microarrays (TMA) were as-
sembled and used. Archival material of 42 patients with
GCT was available. All patients were treated surgically
at the same institution (Department of Gynecology, Uni-
versity of Munich). Tissue biopsies (n = 42) were taken
from representative regions of paraffin-embedded tumor
samples (donor) and arrayed into a new recipient paraf-
fin block by using MTA-1 (Micro Tissue Arrayer) from
Beecher Instruments, USA.
Culture and treatment of KGN
The human ovarian granulosa-like tumor cell line KGN
was obtained from the Riken BioResource Research
Centre (Ibaraki, Japan) [16] and the use of this patented
cell line was approved by T. Yanase. KGN were cultured
in Dulbecco’s Modified Eagle Medium/Nutrient Mixture
F-12 (DMEM/F-12, Thermo Fisher Scientific, Waltham,
MA, USA) supplemented with 10% FCS (Capricorn Sci-
entific GmbH, Ebsdorfergrund, Germany) and 1%
penicillin/streptomycin (Biochrom GmbH, Berlin,
Germany) in T75 flasks (Thermo Fisher Scientific, Wal-
tham, MA, USA) under constant temperature (37 °C)
and CO2 concentration (5%). As KGN change in aggres-
siveness over culture time [19] we used low passages (<
8) and high passages (> 80) for preliminary experiments.
As a passage dependence was absent in terms of sensi-
tivity to BV-6 we proceeded with high passages (> 80).
To rule out serum effects, experiments were executed
in serum-free DMEM/F-12 media. Therefore, KGN were
stimulated for 24 h either with the second mitochondria-
derived activator of caspases (SMAC) mimetic BV-6
(0.05–100 μM; Selleck Chemicals LLC, Houston, TX,
USA) alone or in combination with the pan-caspase in-
hibitor Z-VAD-FMK (1–200 μM; Selleck Chemicals
LLC, Houston, TX, USA). BV-6 and Z-VAD-FMK were
dissolved in water and DMSO (Merck, Darmstadt,
Germany), respectively. Solvent controls were included
in every experiment. To block caspases before cell death
induction, Z-VAD-FMK was applied 2 h prior to BV-6
administration. All experiments were carried out at least
3 times, if not described otherwise.
RT-PCR and qRT-PCR
RT-PCR was conducted as previously described [46, 47].
In brief, total RNA was extracted using RNeasy Plus Micro
Kit (Qiagen, Hilden, Germany) and employed for reverse
transcription. RT-PCR and qRT-PCR primers (Table 1)
were designed using Primer3 and synthesized by metabion
international AG (Planegg, Germany) [48]. The qRT-PCR
analyses were performed utilizing the QuantiFast SYBR
Green PCR Kit (Qiagen, Hilden, Germany). Samples (final
cDNA concentration 10 ng/reaction) were measured in
duplicates in a LightCycler® 96 System (Roche Diagnostics,
Penzberg, Germany; melting at 95 °C for 5min, followed
by 40 cycles of denaturation at 95 °C for 10 s and extension
at 60 °C for 30 s, and a final melting step with continuous
heating (0.5 °C/s from 65 °C to 97 °C) and a cool-down
step at 37 °C for 30 s). Results were calculated using the
2−ΔΔCq method and expression was normalized to riboso-
mal protein L19 (L19), hypoxanthine Phosphoribosyltrans-
ferase 1 (HPRT), peptidylprolyl isomerase A (PPIA) and
TATA-box binding protein (TBP) as endogenous refer-
ences. After PCR, products were separated and visualized
on a 2% agarose gel. Expected bands were cut out,
sequenced (GATC Biotech AG, Konstanz, Germany) and
analyzed using BLAST tool [49].
Immunohistochemistry of ex vivo GCT using anti-cIAP1
antibody
Immunohistochemical staining of cIAP1 proteins to exam-
ine expression patterns in GCTs was done as described in
previous work [46, 47]. Two slides of the TMAs, containing
a total of 42 tumors in duplicates, were used for this study.
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After deparaffinizing, the heat-induced epitope retrieval
(HIER) method was applied to retrieve antigens. Afterwards
endogenous peroxidase was blocked with a methanol
(10%)/H2O2 (3%) solution. Unspecific binding was reduced
by 10% goat serum in PBS. To detect cIAP1 protein, a poly-
clonal antibody was used (HPA005513, Sigma Aldrich, St.
Louis, MO, USA). As a negative control rabbit serum
replaced the primary antiserum. As a secondary antibody a
biotinylated goat anti-rabbit antibody (111–065-144, Jack-
son Immuno Research, Cambridge, UK) was used. After
complexing avidin with biotin (ABC reaction) and staining
by means of 3,3′ diaminobenzidine tetrahydrochloride
(DAB), the slides were counterstained with hematoxylin.
Images were captured using a Zeiss Axiovert microscope
with an Insight Camera (18.2 Color Mosaik). The TMAs
were evaluated by 6 different researchers, who classified
each tumor into one of the three groups (homogenously
strong staining, weak staining/no staining or heteroge-
neous staining).
Confluency measurement and live cell imaging
Confluency was measured as described before [40, 47]. In
brief, 3 × 105 KGN plated on a 60mm2 culture dish (Sar-
stedt AG & Co. KG, Nümbrecht, Germany) were stimu-
lated with BV-6 (EC50, 8 μM) or the solvent control and
monitored for 24 h using the JuLi™ Br Live Cell Analyzer
(NanoEnTek Inc., Seoul, Korea). Pictures were captured
every 20min and confluency was evaluated using the in-
built algorithm. The experiments were repeated 3 times.
Images of KGN, stimulated with 0.1, 1, 10, 50 μM BV-
6, were also captured using a cell culture microscope
with an 10X objective (Leica Biosystems, Wetzlar,
Germany).
Viability measurements using cell counting and ATP-assay
EC50 was identified using 2 different methods. First a cell
counting experiment was carried out with low passages
(< 8) and high passages of KGN (> 80). Therefore 1.5 ×
105 cells were seeded on 6 well plates (Sarstedt AG &
Co. KG, Nümbrecht, Germany) and incubated over night
at 37 °C and 5% CO2. On the next day the cells were
stimulated with BV-6 concentrations ranging from 0.05
to 100 μM or the corresponding solvent control for 24 h.
Afterwards cells were trypsinized and counted using the
CASY® counting system (OMNI Life Science GmbH &
Co KG, Bremen, Germany). Cell counts were normalized
to solvent controls. Experiments were repeated at least 3
times.
The CellTiter-Glo® ATP assay Kit (Promega, Mannheim,
Germany) was perfomed following the manufacturer’s in-
structions. In brief 1 × 104 cells/well (KGN passages > 80)
were seeded in 96-well plates (Sarstedt AG & Co. KG,
Nümbrecht, Germany) and incubated at 37 °C and 5%
CO2. The next day culture media was replaced by
colorless media without supplements. After 2 h, BV-6
(0.1–50 μM) was added and cells were incubated for a
time period of 24 h. Further, BV-6 (8 μM) treatment was
accompanied by different Z-VAD-FMK concentrations
ranging from 0 to 200 μM. Z-VAD-FMK was applied 2 h
before BV-6 stimulation to block caspases. Luminescence
was measured using a plate reader (FLUOstar Optima,
BMG Labtech, Ortenberg, Germany).
Verification of apoptosis hallmarks by Western blot
Apoptosis is a form of cell death that is executed by cas-
pases. Cleavage and therefore activation of caspase 3 is
known to be an intermediate step, which leads to cleavage
of proteins including PARP that is known to be a terminal
step of apoptosis. Therefore, we treated KGN (106 cells/
60mm2 dish (Sarstedt AG & Co. KG, Nümbrecht,
Germany)) with BV-6 (EC50, 8 μM) for 24 h. Afterwards
we generated crude protein extracts using RIPA buffer.
Western Blot was carried out as described before [40, 46].
20 μg/lane protein were loaded on 12% SDS-PAGE gels.
To detect cleaved caspase 3 a specific α-clCASP3 antibody
(#9664, Cell Signaling Technology, Denvers, MA, USA)
was used. To detect a cleavage product of PARP the spe-
cific α-clPARP antibody (#56255, Cell Signaling Technol-
ogy, Denvers, MA, USA) was applied. As a loading control
an α-βActin antibody (A5441, Sigma Aldrich, St. Louis,
MO, USA) was used. For decoration of bound primary
antibody horseradish peroxidase (HRP) conjugated goat
α-rabbit or goat α-mouse antibody (Jackson Immuno Re-
search, Cambridge, UK) were used.
Statistics and graphs
Cell culture and live cell imaging pictures were evaluated
using FIJI [50]. Construction and statistical evaluation of
graphs, including nonlinear regression analyses, were done
in Prism 6 (GraphPad, San Diego, CA, USA). The statis-
tical significance between different staining patterns of tu-
mors was evaluated by one-way ANOVA (Tukey; Geisser-
Greenhouse correction). Effectiveness of Z-VAD-FMK on
BV-6-induced cell death and mRNA expression of NF-κB
regulated genes were evaluated statistically by one sample
t-tests. Final figures were constructed using PowerPoint
for Mac 2013 (Microsoft, Redmond, WA, USA).
Additional file
Additional file 1: Figure S1. Workflow of experiments and effects of
BV-6 on KGN. (a) Schematic workflow of experiments: First EC50 after 24 h
was determined by cell counting and ATP assay in KGN (passage > 80)
and by cell counting in a low passage of KGN (< 8). All further
experiments were carried out with the determined EC50 and with KGN of
higher passages (> 80). Afterwards a Z-VAD-FMK dilution experiment was
carried out, using KGN that were treated with BV-6(EC50,). (b) Live cell
imaging experiment of stimulated KGN (BV-6, 1 μM) versus the
corresponding control for 72 h. The low concentration caused a time-
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dependent effect by reducing number of attached cells. Scale bar =
100 μm (c) Western Blot of BV-6 (EC50, 8 μM)-stimulated KGN and the
corresponding control. An antibody against phosphorylated (p)
MLKL(T357/S358) (ab187091, Abcam, Cambridge, UK) and one against
MLKL (ab184718, Abcam, Cambridge, UK) were examined to explore
possible induction of necroptosis. MLKL bands were visible, whereas the
necroptosis marker (pMLKL) was absent. (TIFF 8189 kb)
Abbreviations
AIF: Apoptosis inducing factor; ATP: Adenosine triphosphate; BIR: Baculoviral
IAP repeats; BIRC: Baculoviral IAP repeat containing protein; CASP8: Caspase
8; cIAP: Cellular inhibitor of apoptosis protein; DAB: 3,3′ diaminobenzidine
tetrahydrochloride; DIABLO: Direct inhibitor of apoptosis protein binding
protein with low PI; EC50: Half maximal effective concentration; FCS: Fetal calf
serum; FOXL2: Forkhead Box L2; GCTs: Granulosa cell tumors; HIER: Heat-
induced epitope retrieval; HPRT: Hypoxanthine phosphoribosyltransferase 1;
HRP: Horseradish peroxidase; HRP: Horseradish peroxidase; HtrA2: High
temperature requirement protein A2; IAPs: Inhibitor of apoptosis proteins;
IL8: Interleukin 8; KGN: Human ovarian granulosa-like tumor cell line;
L19: ribosomal protein L19; MCP-1: Monocyte chemoattractant protein-1;
MLKL: Mixed lineage kinase domain-like protein; mRNA: Messenger
ribonucleic acid; PPIA: Peptidylprolyl isomerase A; TBP: TATA-box binding
protein; α-clCASP3: anti-cleaved caspase 3; α-clPARP: anti-cleaved poly (ADP-
ribose)-polymerase
Acknowledgements
We gratefully acknowledge the expert technical help of Kim Dietrich and
Carola Herrmann.
Ethics approval and consent to participation
The ethical committee of the LMU has approved the study (project 390–15)
and patients had agreed to the use of the tissue for scientific purposes.
Authors’ contributions
Konstantin Bagnjuk and Verena Jasmin Kast performed the cellular studies
and evaluated the results and together with Artur Mayerhofer drafted the
manuscript. Astrid Tiefenbacher performed immunohistochemcial studies.
Melanie Kaseder performed qRT-PCR experiments. Toshihiko Yanase provided
KGN. Dr. Burges was the surgeon and obtained the consent of the patients.
Doris Mayr provided TMA. Lars Kunz, Doris Mayr and Artur Mayerhofer con-
ceived of the study and directed the work. All authors contributed to and
agreed on the final manuscript.
Funding
Deutsche Forschungsgemeinschaft (DFG), MA1080/19–2 (to AM) and
MA4790/4–2 (to DM).
Availability of data and materials
Upon request.
Competing interests
None.
Author details
1Biomedical Center Munich (BMC), Cell Biology, Anatomy III,
Ludwig-Maximilians-University (LMU), Grosshaderner Strasse 9, 82152
Planegg, Germany. 2Department of Endocrinology and Diabetes Mellitus,
Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku,
Fukuoka City, Japan. 3Frauenklinik Campus Großhadern,
Ludwig-Maximilians-University (LMU), Marchioninistraße 15, 81377 Munich,
Germany. 4Division of Neurobiology, Department Biology II,
Ludwig-Maximilians-University (LMU), Grosshaderner Strasse 9, 82152
Planegg, Germany. 5Institute for Pathology, Ludwig-Maximilians-University
(LMU), 80337 Munich, Germany.
Received: 26 April 2019 Accepted: 31 July 2019
References
1. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770.
2. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in
anticancer chemotherapy. Oncogene. 2006;25:4798.
3. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene. 2003;22:8543.
4. Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G, Vandenabeele
P. Toxic proteins released from mitochondria in cell death. Oncogene. 2004;
23(16):2861–74.
5. Fulda S. Promises and challenges of Smac mimetics as Cancer therapeutics.
Clin Cancer Res. 2015;21(22):5030.
6. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg
P, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB
activation, and TNFalpha-dependent apoptosis. Cell. 2007;131(4):669–81.
7. Vince JE, Wong WW-L, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP
antagonists target cIAP1 to induce TNFα-dependent apoptosis. Cell. 2007;
131(4):682–93.
8. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, et al. Autocrine
TNFα signaling renders human Cancer cells susceptible to Smac-mimetic-
induced apoptosis. Cancer Cell. 2007;12(5):445–56.
9. Lu J, Bai L, Sun H, Nikolovska-Coleska Z, McEachern D, Qiu S, et al. SM-164: a
novel, bivalent Smac mimetic that induces apoptosis and tumor regression
by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res.
2008;68(22):9384–93.
10. Vischioni B, van der Valk P, Span SW, Kruyt FAE, Rodriguez JA, Giaccone G.
Expression and localization of inhibitor of apoptosis proteins in normal
human tissues. Hum Pathol. 2006;37(1):78–86.
11. Jamieson S, Fuller PJ. Molecular pathogenesis of granulosa cell tumors of
the ovary. Endocr Rev. 2012;33(1):109–44.
12. Zhou J, Chen Y, Huang Y, Long J, Wan F, Zhang S. Serum follicle-stimulating
hormone level is associated with human epidermal growth factor receptor
type 2 and Ki67 expression in post-menopausal females with breast cancer.
Oncol Lett. 2013;6(4):1128–32.
13. Gründker C, Emons G. The Role of Gonadotropin-Releasing Hormone in Cancer
Cell Proliferation and Metastasis. Frontiers in Endocrinology. 2017;8(187).
14. Lagana AS, Colonese F, Colonese E, Sofo V, Salmeri FM, Granese R, et al.
Cytogenetic analysis of epithelial ovarian cancer's stem cells: an overview
on new diagnostic and therapeutic perspectives. Eur J Gynaecol Oncol.
2015;36(5):495–505.
15. Lagana AS, Sofo V, Vitale SG, Triolo O. Epithelial ovarian cancer inherent
resistance: may the pleiotropic interaction between reduced
immunosurveillance and drug-resistant cells play a key role? Gynecologic
oncology reports. 2016;18:57–8.
16. Nishi Y, Yanase T, Mu Y, Oba K, Ichino I, Saito M, et al. Establishment and
characterization of a steroidogenic human granulosa-like tumor cell line,
KGN, that expresses functional follicle-stimulating hormone receptor.
Endocrinology. 2001;142(1):437–45.
17. Leung DTH, Nguyen T, Oliver EM, Matti J, Alexiadis M, Silke J, et al. Combined
PPARγ activation and XIAP inhibition as a potential therapeutic strategy for
ovarian granulosa cell tumors. Mol Cancer Ther. 2019;18(2):364–75.
18. Zhang Y, Yan Z, Qin Q, Nisenblat V, Chang HM, Yu Y, et al. Transcriptome
Landscape of Human Folliculogenesis Reveals Oocyte and Granulosa Cell
Interactions. Molecular cell. 2018;72(6):1021–34.e4.
19. Imai M, Muraki M, Takamatsu K, Saito H, Seiki M, Takahashi Y. Spontaneous
transformation of human granulosa cell tumours into an aggressive
phenotype: a metastasis model cell line. BMC Cancer. 2008;8(1):319.
20. Stehlik C, De Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J. Nuclear
factor (NF)-κB–regulated X-chromosome–linked iap gene expression
protects endothelial cells from tumor necrosis factor α–induced apoptosis.
J Exp Med. 1998;188(1):211–6.
21. Wang C-Y, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-κB
antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to
suppress caspase-8 activation. Science. 1998;281(5383):1680–3.
22. Kang HB, Kim YE, Kwon HJ, Sok DE, Lee Y. Enhancement of NF-kappaB
expression and activity upon differentiation of human embryonic stem cell
line SNUhES3. Stem Cells Dev. 2007;16(4):615–23.
23. Xing L, Remick DG. Promoter elements responsible for antioxidant
regulation of MCP-1 gene expression. Antioxid Redox Signal. 2007;9(11):
1979–89.
24. Van Noorden CJF. The history of Z-VAD-FMK, a tool for understanding the
significance of caspase inhibition. Acta Histochem. 2001;103(3):241–51.
25. Chaitanya GV, Steven AJ, Babu PP. PARP-1 cleavage fragments: signatures of
cell-death proteases in neurodegeneration. Cell communication and
signaling : CCS. 2010;8:31.
Bagnjuk et al. Journal of Ovarian Research           (2019) 12:76 Page 9 of 10
26. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
2011;144(5):646–74.
27. Dubrez L, Berthelet J, Glorian V. IAP proteins as targets for drug
development in oncology. OncoTargets and therapy. 2013;9:1285–304.
28. Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, Cameron S, et al. Phase I
dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins
inhibitor, in patients with advanced solid tumors. Journal of clinical
oncology : official journal of the American Society of Clinical Oncology.
2014;32(28):3103–10.
29. Bertrand Mathieu JM, Vandenabeele P. The Ripoptosome: death decision in
the cytosol. Mol Cell. 2011;43(3):323–5.
30. Wertz IE, Dixit VM. Signaling to NF-κB: regulation by ubiquitination. Cold
Spring Harb Perspect Biol. 2010;2(3):a003350.
31. Lagana AS, Vitale SG, Nigro A, Sofo V, Salmeri FM, Rossetti P, et al.
Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs)
in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current
Evidence and Future Perspectives. Int J.Mol Sci. 2016;17(7).
32. Vitale SG, Lagana AS, Nigro A, La Rosa VL, Rossetti P, Rapisarda AM, et al.
Peroxisome proliferator-activated receptor modulation during metabolic
diseases and cancers: master and minions. PPAR Res. 2016;2016:6517313.
33. Brumatti G, Ma C, Lalaoui N, Nguyen NY, Navarro M, Tanzer MC, et al. The
caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant
to induce necroptosis and treat acute myeloid leukemia. Sci Transl Med.
2016;8(339):339ra69.
34. McComb S, Aguade-Gorgorio J, Harder L, Marovca B, Cario G, Eckert C,
et al. Activation of concurrent apoptosis and necroptosis by SMAC
mimetics for the treatment of refractory and relapsed ALL. Sci Transl
Med. 2016;8(339):339ra70.
35. Opel D, Schnaiter A, Dodier D, Jovanovic M, Gerhardinger A, Idler I, et al.
Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death
in poor prognostic subgroups of chronic lymphocytic leukemia. Int J
Cancer. 2015;137(12):2959–70.
36. Schirmer M, Trentin L, Queudeville M, Seyfried F, Demir S, Tausch E, et al.
Intrinsic and chemo-sensitizing activity of SMAC-mimetics on high-risk
childhood acute lymphoblastic leukemia. Cell Death Dis. 2016;7:e2052.
37. Steinhart L, Belz K, Fulda S. Smac mimetic and demethylating agents
synergistically trigger cell death in acute myeloid leukemia cells and
overcome apoptosis resistance by inducing necroptosis. Cell Death Dis.
2013;4:e802.
38. Safferthal C, Rohde K, Fulda S. Therapeutic targeting of necroptosis by Smac
mimetic bypasses apoptosis resistance in acute myeloid leukemia cells.
Oncogene. 2017;36(11):1487–502.
39. Chen Q, Kang J, Fu C. The independence of and associations among
apoptosis, autophagy, and necrosis. Signal Transduction and Targeted
Therapy. 2018;3(1):18.
40. Bagnjuk K, Stöckl JB, Fröhlich T, Arnold GJ, Behr R, Berg U, et al. Necroptosis
in primate luteolysis: a role for ceramide. Cell Death Discovery. 2019;5(1):67.
41. Beug ST, Conrad DP, Alain T, Korneluk RG, Lacasse EC. Combinatorial cancer
immunotherapy strategies with proapoptotic small-molecule IAP
antagonists. The International journal of developmental biology. 2015;59(1–
3):141–7.
42. Beug ST, Beauregard CE, Healy C, Sanda T, St-Jean M, Chabot J, et al. Smac
mimetics synergize with immune checkpoint inhibitors to promote tumour
immunity against glioblastoma. Nat Commun. 2017;8.
43. Fischer K, Tognarelli S, Roesler S, Boedicker C, Schubert R, Steinle A, et al.
The Smac Mimetic BV6 Improves NK Cell-Mediated Killing of
Rhabdomyosarcoma Cells by Simultaneously Targeting Tumor and Effector
Cells. Front Immunol. 2017;8(202).
44. Lecis D, De Cesare M, Perego P, Conti A, Corna E, Drago C, et al. Smac
mimetics induce inflammation and necrotic tumour cell death by
modulating macrophage activity. Cell death & disease. 2013;4(11):e920-e.
45. Fulda S. Smac mimetics to therapeutically target IAP proteins in Cancer. Int
Rev Cell Mol Biol. 2017;330:157–69.
46. Du Y, Bagnjuk K, Lawson MS, Xu J, Mayerhofer A. Acetylcholine and
necroptosis are players in follicular development in primates. Sci Rep. 2018;
8(1):6166.
47. Blohberger J, Kunz L, Einwang D, Berg U, Berg D, Ojeda SR, et al.
Readthrough acetylcholinesterase (AChE-R) and regulated necrosis:
pharmacological targets for the regulation of ovarian functions? Cell death
&amp. Disease. 2015;6:e1685.
48. Koressaar T, Remm M. Enhancements and modifications of primer design
program Primer3. Bioinformatics. 2007;23(10):1289–91.
49. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment
search tool. J Mol Biol. 1990;215(3):403–10.
50. Rueden CT, Schindelin J, Hiner MC, DeZonia BE, Walter AE, Arena ET, et al.
ImageJ2: ImageJ for the next generation of scientific image data. BMC
bioinformatics. 2017;18(1):529.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Bagnjuk et al. Journal of Ovarian Research           (2019) 12:76 Page 10 of 10
